Skip to main content
Hemostemix Inc. logo

Hemostemix Inc. — Investor Relations & Filings

Ticker · HEM ISIN · CA4236943060 LEI · 984500C65BB0B8159L77 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 576 across all filing types
Latest filing 2022-08-15 Capital/Financing Update
Country CA Canada
Listing TSXV HEM

About Hemostemix Inc.

https://hemostemix.com/

Hemostemix Inc. is a clinical-stage biotechnology company specializing in regenerative medicine through the development and commercialization of autologous (patient's own) blood-derived stem cell therapies. The company's lead investigational product is ACP-01 (Angiogenic Precursor Cell treatment), a platform targeting ischemic conditions such as Critical Limb Ischemia (CLI), ischemic cardiomyopathy, and angina. ACP-01 is designed to address unmet medical needs, particularly in patients ineligible for standard revascularization procedures. Phase II clinical data re-examination for "no option" CLI indicated that ACP-01 administration was safe and associated with reduced ulcer size and decreased rates of amputation and death.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of the second tranche of a private placement financing by Hemostemix Inc. It details the issuance of units, pricing, warrants, finder fees, use of proceeds, and regulatory approvals. There is no financial statement or detailed financial analysis included, only an update on a financing transaction. The document is not a full financial report, earnings release, or management discussion. It is a capital/financing update about a private placement closing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just a brief announcement or regulatory filing. Confidence is high due to clear content and context.
2022-08-15 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings
2022-08-12 English
Other.pdf
Regulatory Filings Classification · 100% confidence The document is a certificate of an officer (Thomas Smeenk, President, CEO & Director) certifying compliance with National Instrument 54-101 regarding communications with beneficial owners of securities for a special meeting of shareholders. It is a formal attestation letter related to regulatory compliance and proxy materials distribution. The document does not contain financial data, report content, or detailed financial analysis. It is primarily an officer certification letter submitted to Canadian securities regulatory authorities. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS). The document length is short (1479 characters), and it is not a report or announcement of a report but a certification letter.
2022-08-04 English
Notice of meeting - English.pdf
Regulatory Filings
2022-08-04 English
Management information circular - English.pdf
Regulatory Filings
2022-08-04 English
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a form from Computershare allowing shareholders to request to receive Interim Financial Statements or Annual Financial Statements by mail. It is not the financial statements themselves, nor does it contain any financial data or analysis. The document is short (2248 characters) and serves as a request or notification form related to financial reports, not the reports themselves. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-08-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.